USP13 and neoplasm: Importantly, in addition to apply genetic approaches to modulate USP13 expression, we have tested a preclinical lead compound spautin-1 and evaluated the impact of pharmacologically inhibiting USP13 activity on MCL1 protein expression and tumor cell sensitivity to ABT-263.